"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
| Descriptor ID |
D008687
|
| MeSH Number(s) |
D02.078.370.141.450
|
| Concept/Terms |
Metformin- Metformin
- Dimethylbiguanidine
- Dimethylguanylguanidine
|
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in this website by year, and whether "Metformin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 1 | 2 |
| 2005 | 0 | 3 | 3 |
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 7 | 0 | 7 |
| 2011 | 2 | 3 | 5 |
| 2012 | 3 | 1 | 4 |
| 2013 | 3 | 0 | 3 |
| 2014 | 6 | 1 | 7 |
| 2015 | 4 | 1 | 5 |
| 2016 | 4 | 4 | 8 |
| 2017 | 2 | 3 | 5 |
| 2018 | 2 | 4 | 6 |
| 2019 | 3 | 2 | 5 |
| 2020 | 7 | 4 | 11 |
| 2021 | 6 | 2 | 8 |
| 2022 | 2 | 1 | 3 |
| 2023 | 7 | 0 | 7 |
| 2024 | 4 | 2 | 6 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metformin" by people in Profiles.
-
Differential Treatment Effects on ?-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2025 Apr 01; 48(4):623-631.
-
Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway. Cell Rep Med. 2025 Feb 18; 6(2):101941.
-
A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. Gynecol Oncol. 2025 Feb; 193:73-80.
-
Insulin clearance at randomisation and in response to treatment in youth with type 2 diabetes: a secondary analysis of the TODAY randomised clinical trial. Diabetologia. 2025 Mar; 68(3):676-687.
-
The Effects of Metformin on Cisplatin-Induced Ototoxicity in Diabetic Patients. Otolaryngol Head Neck Surg. 2025 Jan; 172(1):243-253.
-
Initiation of metformin in early pregnancy results in fetal bioaccumulation, growth restriction, and renal dysmorphology in a primate model. Am J Obstet Gynecol. 2024 Sep; 231(3):352.e1-352.e16.
-
Long-term combination therapy with metformin and oxymetholone in a Fanconi anemia mouse model. Pediatr Blood Cancer. 2024 Aug; 71(8):e31030.
-
Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes. J Clin Endocrinol Metab. 2024 Apr 19; 109(5):1361-1370.
-
Impact of Insulin Sensitivity and ?-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy. Diabetes Care. 2024 Apr 01; 47(4):571-579.
-
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy. Am Fam Physician. 2024 04; 109(4):333-342.